Strategic R&D transactions in personalized drug development

Tomohiro Makino, Yeongjoo Lim, Kota Kodama

Index: 10.1016/j.drudis.2018.03.009

Full Text: HTML

Abstract

Highlights • Personalized medicine is the focus of investment in start-up companies. • This trend is expected to generate more patents in the area. • Number of R＆D licenses is an indicator of the financing deals in the area. • Start-ups and their investors could lead the progress of personalized medicine. Although external collaboration capability influences the development of personalized medicine, key transactions in the pharmaceutical industry have not been addressed. To explore specific trends in interorganizational transactions and key players, we longitudinally surveyed strategic transactions, comparing them with other advanced medical developments, such as antibody therapy, as controls. We found that the financing deals of start-ups have surged over the past decade, accelerating intellectual property (IP) creation. Our correlation and regression analyses identified determinants of financing deals among alliance deals, acquisition deals, patents, research and development (R&D) licenses, market licenses, and scientific papers. They showed that patents positively correlated with transactions, and that the number of R&D licenses significantly predicted financing deals. This indicates, for the first time, that start-ups and investors lead progress in personalized medicine.